Immune checkpoint inhibitors (ICIs) have dramatically improved the treatment of many tumours, but only a subset of patients respond when ICIs are used as standalone immunotherapeutic interventions. Here, Galluzzi and colleagues discuss the potential of harnessing clinical agents that target oncogene and non-oncogene addiction to enhance ICI sensitivity by converting immunologically ‘cold’ tumours into ‘hot’ lesions.
- Giulia Petroni
- Aitziber Buqué
- Lorenzo Galluzzi
